Changes in the perceived epidemiology of amyloidosis: 20 year-experience from a Tertiary Referral Centre in Tuscany.

[1]  C. Di Mario,et al.  Incidence of light chain amyloidosis in Florence metropolitan area, Italy: a population-based study , 2021, Amyloid : the international journal of experimental and clinical investigation : the official journal of the International Society of Amyloidosis.

[2]  A. Wechalekar,et al.  Epidemiologic and Survival Trends in Amyloidosis, 1987-2019. , 2020, The New England journal of medicine.

[3]  C. Di Mario,et al.  Biomarkers and Prediction of Prognosis in Transthyretin-Related Cardiac Amyloidosis: Direct Comparison of Two Staging Systems. , 2020, The Canadian journal of cardiology.

[4]  J. Moon,et al.  Cardiac amyloidosis in aortic stenosis: The tip of the iceberg. , 2018, The Journal of thoracic and cardiovascular surgery.

[5]  George H Sack,et al.  Serum amyloid A – a review , 2018, Molecular Medicine.

[6]  A. Petrie,et al.  A new staging system for cardiac transthyretin amyloidosis , 2018, European heart journal.

[7]  M. Leon,et al.  Unveiling transthyretin cardiac amyloidosis and its predictors among elderly patients with severe aortic stenosis undergoing transcatheter aortic valve replacement , 2017, European heart journal.

[8]  C. Rapezzi,et al.  Clinical characteristics of wild-type transthyretin cardiac amyloidosis: disproving myths , 2017, European heart journal.

[9]  Giampaolo Merlini,et al.  Amyloid fibril proteins and amyloidosis: chemical identification and clinical classification International Society of Amyloidosis 2016 Nomenclature Guidelines , 2016, Amyloid : the international journal of experimental and clinical investigation : the official journal of the International Society of Amyloidosis.

[10]  James C Moon,et al.  Nonbiopsy Diagnosis of Cardiac Transthyretin Amyloidosis , 2016, Circulation.

[11]  E. González-López,et al.  Wild-type transthyretin amyloidosis as a cause of heart failure with preserved ejection fraction. , 2015, European heart journal.

[12]  A. Foli,et al.  A European collaborative study of cyclophosphamide, bortezomib, and dexamethasone in upfront treatment of systemic AL amyloidosis. , 2015, Blood.

[13]  A. Cheung,et al.  Pathology of transcatheter valve therapy. , 2012, JACC. Cardiovascular interventions.

[14]  C. Selmi,et al.  Currents Concepts on the Immunopathology of Amyloidosis , 2010, Clinical reviews in allergy & immunology.

[15]  F. Salvi,et al.  Usefulness of 99mTc-DPD scintigraphy in cardiac amyloidosis. , 2008, Journal of the American College of Cardiology.

[16]  A. Singleton,et al.  Senile systemic amyloidosis affects 25% of the very aged and associates with genetic variation in alpha2‐macroglobulin and tau: A population‐based autopsy study , 2008, Annals of medicine.

[17]  P. Hawkins,et al.  Systemic amyloidosis. , 2006, Current opinion in pharmacology.

[18]  F. Salvi,et al.  Noninvasive etiologic diagnosis of cardiac amyloidosis using 99mTc-3,3-diphosphono-1,2-propanodicarboxylic acid scintigraphy. , 2005, Journal of the American College of Cardiology.

[19]  R A Kyle,et al.  Frequency and distribution of senile cardiovascular amyloid. A clinicopathologic correlation. , 1983, The American journal of medicine.